Topiramate as a treatment for Co-occurring AUD and PTSD
托吡酯治疗同时发生的 AUD 和 PTSD
基本信息
- 批准号:10473681
- 负责人:
- 金额:$ 43.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-20 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAlcohol consumptionAlcoholsAllelesAnimal ModelAnticonvulsantsApoptosisBiological MarkersBrain ChemistryChronicClinicalClinical ResearchClinical TreatmentCodeDataDiseaseDoseDouble-Blind MethodEffectivenessFDA approvedGenesGenetic PolymorphismGenotypeGlutamatesHomozygoteHumanKainic Acid ReceptorsMagnetic Resonance SpectroscopyMeasuresMethodsNeurobiologyNeurocognitiveNeuropeptidesOutcomeOxidative StressParticipantPatientsPharmaceutical PreparationsPharmacotherapyPlacebosPlasmaPopulationPost-Traumatic Stress DisordersPrediction of Response to TherapyProbabilityPsychotherapyRandomizedRandomized Clinical TrialsRandomized Controlled TrialsResearchRewardsSamplingStressSymptomsTestingWorkalcohol abuse therapyalcohol cuealcohol effectalcohol exposurealcohol responsealcohol use disorderanxiety-like behaviorbiological adaptation to stressclinical predictorsclinically relevantcomorbiditydrinkingexecutive functionfunctional magnetic resonance imaging/electroencephalographyglutamatergic signalinghypothalamic-pituitary-adrenal axisincentive saliencenegative affectneuroimagingneuroimaging markerneuroinflammationneurotrophic factoropen labelpersonalized medicinepre-clinicalresponsetopiramatetreatment grouptrial design
项目摘要
Summary
Alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) are highly comorbid, and
present a clinical challenge for which existing treatments have limited efficacy. Existing clinical evidence
suggests treatments that simultaneously address symptoms of both PTSD and AUD should be more
efficacious than treating either disorder in isolation. The overlap in the neurobiological basis of PTSD and AUD
(involving alterations in incentive salience, stress/negative affect, and executive control network functioning)
suggests that there could be treatments that would effectively treat both disorders. However, there is no
pharmacotherapy or psychotherapy treatment that is clearly effective for both disorders.
Topiramate, an FDA-approved anticonvulsant with effects on GABAergic and glutamatergic signaling,
has demonstrated efficacy in the treatment of AUD in several randomized clinical trials (RCTs), and has also
been tested in several open-label and small RCTs for treatment of PTSD with some evidence of effectiveness.
Positive results in one open-label trial and one small RCT in patients with co-occurring PTSD and AUD
suggest that topiramate may have beneficial effects on symptoms of both PTSD and AUD in this population.
Preclinical work also supports the efficacy of topiramate in ameliorating anxiety-like behavior and altered stress
response in animal models of stress and chronic alcohol exposure. A recent clinical study demonstrated that
the effects of topiramate on alcohol use were moderated by a polymorphism of the GRIK1 gene (coding for the
kainate receptor GluK1 subunit), such that significant benefit was found only among rs2832407 C-allele
homozygotes.
The proposed study, Project 2 of the proposed center, is a double-blind, 2-group randomized controlled
trial evaluating the effects of topiramate, in contrast to those of placebo, in patients with comorbid PTSD and
moderate-to-severe AUD. The proposed trial will provide one of the first rigorous tests of whether the effects of
topiramate in AUD generalize to patients with co-occurring PTSD, and one of the first rigorous tests of whether
topiramate has beneficial effects on PTSD symptoms in this population. It will be the first study to test whether
the rs2832407 genotype predicts clinical response to topiramate for AUD and PTSD in patients with both
disorders. Further, it will contribute to the understanding of topiramate’s mechanisms of action in the co-morbid
AUD/PTSD population, and to the discovery of predictors of treatment response. In support of the overall aims
of the center, the trial will serve as a platform for studies of topiramate’s effects on brain chemistry and function
as measured by MR spectroscopy, fMRI, and EEG (Project 3). Data from Project 2 will also contribute to
Overall Center Aims investigating the relationship of plasma biomarkers in Project 2 to plasma biomarkers in
Project 1, and the relationship of plasma biomarkers in Project 2 to neuroimaging markers in Project 3.
概括
酒精使用障碍(AUD)和创伤后应激障碍(PTSD)高度合并,并且
提出临床挑战,现有治疗的有效性有限。现有的临床证据
建议仅解决PTSD和AUD症状的治疗方法应该更多
这比孤立地治疗任何一种疾病都是有效的。 PTSD和AUD的神经生物学基础的重叠
(涉及激励显着性,压力/负面影响和执行控制网络功能的改变)
表明可能会有有效治疗这两种疾病的治疗方法。但是,没有
药物疗法或心理治疗对两种疾病显然有效。
托吡酯,一种经FDA批准的抗惊厥药,对GABA能和谷氨酸能信号的影响,
在几项随机临床试验(RCT)中,已经证明了AUD治疗的效率,并且也已有
我们在几个开放标签和小的RCT中进行了测试,用于治疗PTSD,并具有一些有效性的证据。
一项开放标签试验的阳性结果和同时发生的PTSD和AUD患者的一个小RCT
表明topramate在该人群中可能对PTSD和AUD的症状产生有益的影响。
临床前工作还支持topramate在改善动画样行为和改变压力方面的效率
在压力和慢性酒精暴露的动物模型中的反应。最近的一项临床研究表明
通过Grik1基因的多态性,可以调节甲胺对饮酒的影响(编码
海藻酸盐接收器gluk1亚基),因此仅在RS2832407 C-Allele中发现了巨大的益处
纯合子。
拟议中心的拟议研究2是双盲,2组随机对照
与安慰剂相比,在合并症患者和安慰剂的患者中,评估甲板酸酯的影响
中度至重度音频。拟议的试验将提供第一个严格的测试之一
topramate在AUD中概括了同时发生的PTSD患者,这是第一个严格的测试之一
托吡酯对该人群中的PTSD症状具有有益的影响。这将是测试是否的研究
RS2832407基因型预测对AUD和PTSD的Topramate的临床反应,
疾病。此外,它将有助于理解托普拉梅特的合并症中的作用机制
AUD/PTSD人群,并发现治疗反应的预测指标。支持总体目标
在该中心,该试验将作为研究topramate对大脑化学和功能影响的平台
通过MR光谱,fMRI和EEG测量(项目3)。项目2的数据也将有助于
总体中心旨在研究项目2中等离子体生物标志物与等离子生物标志物的关系
项目1,项目2中的等离子体生物标志物与项目3中的神经成像标记的关系。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Parks Bogenschutz其他文献
Michael Parks Bogenschutz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Parks Bogenschutz', 18)}}的其他基金
Topiramate as a treatment for Co-occurring AUD and PTSD
托吡酯治疗同时发生的 AUD 和 PTSD
- 批准号:
10237285 - 财政年份:2018
- 资助金额:
$ 43.38万 - 项目类别:
Comparing Interventions for Opioid Dependent Patients Presenting in Medical EDs
比较对就诊于急诊室的阿片类药物依赖患者的干预措施
- 批准号:
9131691 - 财政年份:2013
- 资助金额:
$ 43.38万 - 项目类别:
Comparing Interventions for Opioid Dependent Patients Presenting in Medical EDs
比较对就诊于急诊室的阿片类药物依赖患者的干预措施
- 批准号:
8416794 - 财政年份:2013
- 资助金额:
$ 43.38万 - 项目类别:
Comparing Interventions for Opioid Dependent Patients Presenting in Medical EDs
比较对就诊于急诊室的阿片类药物依赖患者的干预措施
- 批准号:
8735111 - 财政年份:2013
- 资助金额:
$ 43.38万 - 项目类别:
A Program of Research and Mentorship on Alcoholism and Co-occuring Disorders
关于酗酒和并发疾病的研究和指导计划
- 批准号:
8133156 - 财政年份:2007
- 资助金额:
$ 43.38万 - 项目类别:
A Program of Research and Mentorship on Alcoholism and Co-occuring Disorders
关于酗酒和并发疾病的研究和指导计划
- 批准号:
7498960 - 财政年份:2007
- 资助金额:
$ 43.38万 - 项目类别:
A Program of Research and Mentorship on Alcoholism and Co-occuring Disorders
关于酗酒和并发疾病的研究和指导计划
- 批准号:
7313637 - 财政年份:2007
- 资助金额:
$ 43.38万 - 项目类别:
A Program of Research and Mentorship on Alcoholism and Co-occuring Disorders
关于酗酒和并发疾病的研究和指导计划
- 批准号:
7682269 - 财政年份:2007
- 资助金额:
$ 43.38万 - 项目类别:
12-Step Facilitation for the Dually Diagnosed
为双重诊断患者提供 12 步便利
- 批准号:
7115813 - 财政年份:2005
- 资助金额:
$ 43.38万 - 项目类别:
12-Step Facilitation for the Dually Diagnosed
为双重诊断患者提供 12 步便利
- 批准号:
6970257 - 财政年份:2005
- 资助金额:
$ 43.38万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Elucidating causal mechanisms of ethanol-induced analgesia in BXD recombinant inbred mouse lines
阐明 BXD 重组近交系小鼠乙醇诱导镇痛的因果机制
- 批准号:
10825737 - 财政年份:2023
- 资助金额:
$ 43.38万 - 项目类别:
Circuit control of motivation to take and seek alcohol
饮酒和寻求酒精动机的电路控制
- 批准号:
10753712 - 财政年份:2023
- 资助金额:
$ 43.38万 - 项目类别:
Mindfulness and Behavior Change to Reduce Cardiovascular Disease Risk in Older People with HIV
正念和行为改变可降低老年艾滋病毒感染者的心血管疾病风险
- 批准号:
10762220 - 财政年份:2023
- 资助金额:
$ 43.38万 - 项目类别:
Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
- 批准号:
10456380 - 财政年份:2023
- 资助金额:
$ 43.38万 - 项目类别:
Alcohol use, physical activity, and neurophysiological indicators of behavioral adaptability
饮酒、体力活动和行为适应性的神经生理学指标
- 批准号:
10609697 - 财政年份:2023
- 资助金额:
$ 43.38万 - 项目类别: